You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信邦製藥(002390.SZ):擬7.5億元轉讓中肽生化及康永生物各100%股權
格隆匯 06-14 17:11

格隆匯6月14日丨信邦製藥(002390.SZ)公佈,公司全資子公司中肽生化有限公司(“中肽生化”)、康永生物有限公司(“康永生物”)主要從事多肽原料藥定制化服務和體外診斷試劑銷售,業務主要集中在北美地區,2019年多肽和體外診斷試劑銷售收入分別佔公司主營業務收入的4.18%0.76%。受中美貿易摩擦、新冠肺炎疫情等不利因素的影響,公司多肽業務、體外診斷試劑業務均面臨了發展瓶頸,康永生物2019年度和中肽生化2020年一季度都出現了虧損。為尋求破局需要考慮進一步增加研發投入並在境外投資建廠,大額的資金投入短期內必然會對上市公司整體經營業績、財務狀況造成不利影響。

因此,為避免上述不確定性為上市公司持續盈利能力造成風險,優化公司資產結構,更好地配置公司資源,貫徹聚焦醫療服務的發展戰略,公司擬將中肽生化100%股權及康永生物100%股權轉讓給泰德醫藥(浙江)有限公司(“泰德醫藥”),股權轉讓款合計為人民幣7.5億元,其中中肽生化100%股權的轉讓價格為人民幣7.183億元,康永生物100%股權的轉讓價格為人民幣3170萬元。

上述股權出售完成後,中肽生化及康永生物將不再是公司子公司,不再納入公司合併報表範圍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account